权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Rapid Molecular Diagnostics For New&Emerging SARS-CoV-2 Variants of Concern-Protecting Vaccine Efficacy

新的快速分子诊断

基本信息

批准号：
BB/W003562/1
负责人：
Tomasz Jurkowski
金额：
$ 10.26万
依托单位：
CARDIFF UNIVERSITY
依托单位国家：
英国
项目类别：
Research Grant
财政年份：
2021
资助国家：
英国
起止时间：
2021 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=BB%2FW003562%2F1
关键词：
Rapid Molecular Diagnostics New&Emerging SARS

项目摘要

Despite the successful development of several efficacious vaccines, the COVID-19 pandemic continues to threaten the UK and global populations. Whilst vaccinations efforts have been hugely successful and provide the basis to facilitate opening up of society and a return to normality, the emergence of SARS-CoV-2 variants capable of evading the immune response endanger the efficacy of the vaccination strategy. To preserve the efficacy of SARS-CoV-2 vaccination in the UK population, aggressive and rapid surveillance for known and emerging SARS-CoV-2 variants of concern (VoCs) is required. Rapid and specific molecular diagnostics can provide speed and coverage advantages compared to genomic sequencing alone, benefitting the public health response to facilitate containment. In this project, we expand our recently developed SARS-CoV-2 variant-specific detection technology to allow rapid discrimination of variants of concern. This approach can be implemented directly and immediately on positive samples in the pipelines of large testing facilities or developed for Point of Care (PoC) use. This technology will complement the current genomic sequencing efforts that allow identification of new and existing VoCs and facilitate lineage tracking, with rapid molecular diagnostics able to assist the public health response by identifying key variants without the delay and sub-sampling associated with genomic sequencing, therefore allowing a rapid and agile response to aid breaking chains of transmission and facilitate containment before widespread community transmission occurs.

尽管成功开发了几种有效的疫苗，但COVID-19大流行继续威胁英国和全球人口。虽然疫苗接种工作取得了巨大成功，并为促进社会开放和恢复正常提供了基础，但能够逃避免疫反应的SARS-CoV-2变体的出现危及疫苗接种策略的有效性。为了保持SARS-CoV-2疫苗在英国人群中的有效性，需要对已知和新出现的SARS-CoV-2变异株（VoC）进行积极和快速的监测。与单独的基因组测序相比，快速和特异的分子诊断可以提供速度和覆盖率优势，有利于公共卫生反应，以促进遏制。在这个项目中，我们扩展了我们最近开发的SARS-CoV-2变异特异性检测技术，以快速区分所关注的变异。这种方法可以直接和立即在大型检测设施的管道中的阳性样本上实施，或者开发用于护理点（Point of Care，简称POS）使用。这项技术将补充目前的基因组测序工作，允许识别新的和现有的VoC并促进谱系跟踪，快速分子诊断能够通过识别关键变体来帮助公共卫生应对，而无需与基因组测序相关的延迟和子采样，因此，可以迅速而敏捷地作出反应，帮助切断传播链，并在社区传播广泛之前进行遏制发生。